1. Home
  2. INLF vs LUNG Comparison

INLF vs LUNG Comparison

Compare INLF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INLF

INLIF LIMITED

HOLD

Current Price

$3.19

Market Cap

70.7M

Sector

Industrials

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.26

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLF
LUNG
Founded
2016
1995
Country
China
United States
Employees
156
N/A
Industry
Industrial Machinery/Components
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.7M
57.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
INLF
LUNG
Price
$3.19
$1.26
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
49.3K
297.1K
Earning Date
03-06-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.24
$1.13
52 Week High
$5.20
$5.46

Technical Indicators

Market Signals
Indicator
INLF
LUNG
Relative Strength Index (RSI) 60.72 38.77
Support Level $0.40 $1.13
Resistance Level $5.20 $1.64
Average True Range (ATR) 0.20 0.09
MACD -0.13 -0.01
Stochastic Oscillator 0.00 4.03

Price Performance

Historical Comparison
INLF
LUNG

About INLF INLIF LIMITED

INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. Its portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: